MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 561303 | Name: SPL-334
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SPL-334 is an inhibitor of S-nitrosoglutathione reductase. SPL-334 prevents weight loss, attenuating lung inflammation and fibrosis in a bleomycin injury model of interstitial lung disease in mice.

Chemical Structure

SPL-334
SPL-334
CAS#688347-51-5

Theoretical Analysis

MedKoo Cat#: 561303

Name: SPL-334

CAS#: 688347-51-5

Chemical Formula: C22H15N3O3S2

Exact Mass: 433.0555

Molecular Weight: 433.50

Elemental Analysis: C, 60.96; H, 3.49; N, 9.69; O, 11.07; S, 14.79

Price and Availability

Size Price Availability Quantity
5mg USD 450.00 2 weeks
25mg USD 900.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
SPL-334; SPL334; SPL 334
IUPAC/Chemical Name
4-[[2-[(2-Cyanophenyl)methylsulfanyl]-4-oxothieno[3,2-d]pyrimidin-3-yl]methyl]benzoic acid
InChi Key
UWWSCLNCHCROLL-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H15N3O3S2/c23-11-16-3-1-2-4-17(16)13-30-22-24-18-9-10-29-19(18)20(26)25(22)12-14-5-7-15(8-6-14)21(27)28/h1-10H,12-13H2,(H,27,28)
SMILES Code
O=C(O)C1=CC=C(CN(C(SCC2=CC=CC=C2C#N)=NC3=C4SC=C3)C4=O)C=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
SPL-334 causes a significant reduction in the production of Th2 cytokines IL-5 and IL-13 and the levels of the chemokine CCL11 (eotaxin-1) in the airways.
In vitro activity:
To be determined
In vivo activity:
SPL-334 shows promise as a potential therapeutic agent for interstitial lung disease (ILD). In a mouse model of ILD induced by bleomycin, daily administration of SPL-334 showed no toxicity and prevented weight loss and cellular changes induced by bleomycin. When administered therapeutically, SPL-334 reduced weight loss, cellular changes, and collagen accumulation in the lungs, accompanied by decreased levels of profibrotic cytokines. Reference: J Pharmacol Exp Ther. 2015 Oct;355(1):13-22. https://pubmed.ncbi.nlm.nih.gov/26209236/
Solvent mg/mL mM comments
Solubility
DMSO 20.0 46.14
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 433.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Luzina IG, Lockatell V, Todd NW, Kopach P, Pentikis HS, Atamas SP. Pharmacological In Vivo Inhibition of S-Nitrosoglutathione Reductase Attenuates Bleomycin-Induced Inflammation and Fibrosis. J Pharmacol Exp Ther. 2015 Oct;355(1):13-22. doi: 10.1124/jpet.115.224675. Epub 2015 Jul 24. PMID: 26209236. 2. Ferrini ME, Simons BJ, Bassett DJ, Bradley MO, Roberts K, Jaffar Z. S-nitrosoglutathione reductase inhibition regulates allergen-induced lung inflammation and airway hyperreactivity. PLoS One. 2013 Jul 25;8(7):e70351. doi: 10.1371/journal.pone.0070351. PMID: 23936192; PMCID: PMC3723687.
In vitro protocol:
To be determined
In vivo protocol:
1. Luzina IG, Lockatell V, Todd NW, Kopach P, Pentikis HS, Atamas SP. Pharmacological In Vivo Inhibition of S-Nitrosoglutathione Reductase Attenuates Bleomycin-Induced Inflammation and Fibrosis. J Pharmacol Exp Ther. 2015 Oct;355(1):13-22. doi: 10.1124/jpet.115.224675. Epub 2015 Jul 24. PMID: 26209236. 2. Ferrini ME, Simons BJ, Bassett DJ, Bradley MO, Roberts K, Jaffar Z. S-nitrosoglutathione reductase inhibition regulates allergen-induced lung inflammation and airway hyperreactivity. PLoS One. 2013 Jul 25;8(7):e70351. doi: 10.1371/journal.pone.0070351. PMID: 23936192; PMCID: PMC3723687.
1: Luzina IG, Lockatell V, Todd NW, Kopach P, Pentikis HS, Atamas SP. Pharmacological In Vivo Inhibition of S-Nitrosoglutathione Reductase Attenuates Bleomycin-Induced Inflammation and Fibrosis. J Pharmacol Exp Ther. 2015 Oct;355(1):13-22. doi: 10.1124/jpet.115.224675. Epub 2015 Jul 24. PubMed PMID: 26209236. 2: Ferrini ME, Simons BJ, Bassett DJ, Bradley MO, Roberts K, Jaffar Z. S-nitrosoglutathione reductase inhibition regulates allergen-induced lung inflammation and airway hyperreactivity. PLoS One. 2013 Jul 25;8(7):e70351. doi: 10.1371/journal.pone.0070351. PMID: 23936192; PMCID: PMC3723687. 3: Hayashida K, Bagchi A, Miyazaki Y, Hirai S, Seth D, Silverman MG, Rezoagli E, Marutani E, Mori N, Magliocca A, Liu X, Berra L, Hindle AG, Donnino MW, Malhotra R, Bradley MO, Stamler JS, Ichinose F. Improvement in Outcomes After Cardiac Arrest and Resuscitation by Inhibition of S-Nitrosoglutathione Reductase. Circulation. 2019 Feb 5;139(6):815-827. doi: 10.1161/CIRCULATIONAHA.117.032488. PMID: 30586713; PMCID: PMC6361681.